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Abstract
An increase in abundance and activity of N-methyl D-aspartate receptors (NMDAR)
was previously reported for red blood cells (RBCs) of sickle cell disease (SCD) patients.
Increased Ca2+ uptake through the receptor supported dehydration and RBC damage.
In a pilot phase IIa-b clinical trial MemSID, memantine, a blocker of NMDAR, was used
for treatment of four patients for 12 months. Two more patients that have enrolled
into the study did not finish it. One of them had psychotic event following the invol-
untary overdose of the drug, whereas the other had vertigo and could not comply to
the trial visits schedule. Acute and durable responses of RBCs of SCD patients to daily
oral administrationofmemantineweremonitored.MarkersofRBCturnover, changes in
cell density, and alterations in ion handling and RBCmorphology were assessed. Acute
transient shifts in intracellular Ca2+, volume and density, and reduction in plasma lac-
tate dehydrogenate activitywere observed alreadywithin the firstmonth of treatment.
Durable effects of memantine included (a) decrease in reticulocyte counts, (b) reduc-
tion in reticulocyte hemoglobinization, (c) advanced membrane maturation and its sta-
bilization as follows from reduction in the number of NMDAR per cell and reduction in
hemolysis, and (iv) rehydration and decrease in K+ leakage frompatients’ RBC.Meman-
tine therapy resulted in reduction in number of cells with sickle morphology that was
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sustained at least over 2 months after therapy was stopped indicating an improvement
in RBC longevity.
1 INTRODUCTION
Sickle cell disease (SCD) is recognized by the World Health Orga-
nization as a featured global mortality burden [1]. The cause of this
disease is a point mutation in the 𝛽 globin chain making the deoxy-
genated form of hemoglobin S (HbS) poorly soluble and prone to
form rod-shape complexes that gives the cells famous “sickle” or
“holy leaf” morphology, damages the membrane, and makes RBCs of
SCD patients stiff and short-lived [2,3]. Deoxygenation, dehydration,
and inflammation trigger HbS aggregation, red blood cell (RBC)
membrane damage, and ultimately result in production of terminally
sickled, highly adherent and fragile cells. This condition is associated
with hemolysis, vaso-occlusive crises (VOCs) and pain episodes, and
requires hospitalization, analgesics, and blood transfusions [4,5].
Preventive approaches include infection prophylaxis and chronic
hydroxyurea (HU) that induces production of fetal hemoglobin (HbF)
by a mechanism not yet fully understood, possibly involving the nitric
oxide (NO)-driven signaling pathway [2,6-8]. Some SCD patients
remain refractive to HU treatment, the others may suffer from a
number of side effects [9]. Three further drugs, L-glutamine, Voxelotor,
and Crizanlizumab-tmca, were recently approved for treatment of
symptomatic SCD [10]. L-Glutamine is presumably acts via antioxidant
supporting NADH production [11]. Monoclonal anti-P-selectin anti-
body Crizanlizumab targets vaso-occlusion [12], whereas Voxelotor
increases O2 affinity of HbS interfering with its aggregation [13].
Several other drugs have been tested, some of which failed, the others
being at different stages of testing in clinical trials [10].
An alternative strategy aiming at counteraction of aggregation of
HbS was based on targeting dehydration of RBC, reduction in mean
corpuscular hemoglobin concentration (MCHC), and thus limiting the
interaction between the HbS molecules. The drug of choice, Gardos
channel blocker Senicapoc, successfully decreased hemolytic activity
but failed to affect the incidence of VOCs [14]. Abnormally high activ-
ity of Gardos channels is supported by accelerated Ca2+ uptake into
RBCs of SCD patients. Apart from activation of Gardos channels, Ca2+
overload stimulates NADPH oxidases and promotes proteolytic activ-
ity of𝜇-calpain [15].Wehave identifiedN-methylD-aspartate receptor
(NMDAR) as one of the ion channels involved in abnormally high Ca2+
uptake in RBCs of SCD patients [16]. In vitro treatment of patients’
RBCs with the channel blockers, memantine or MK-801, caused rehy-
dration, reduced the amount of oxidized glutathione, and interfered
with sickling [16]. Based on these ex vivo findings, a group of six SCD
patents observed at the Clinic ofMedical Oncology andHematology at
the University Hospital Zurich were enrolled into a pilot phase II study
in which Memantin Mepha was applied to those patients. The primary
objective of the clinical study “Safety and tolerability of Memantin
Mepha in Sickle Cell Disease Patients (MemSID)” was to assess safety
and tolerability of the drug already approved worldwide for treatment
of dementia [17,18] for a group of patients with a different disease.
Findings on safety and tolerability of memantine therapy as well as
the changes in the quality of life of patients within the MemSID trial
are out of the scope of this manuscript and will be summarized else-
where [19]. We have profited from a unique possibility to assess acute
and durable responses of RBCs of SCD patients to the drug-blocking
NMDARs. In order to investigate the impact ofmemantine on theRBCs
form patients suffering from SCD, changes in RBC production rate,
hemolytic activity, RBC stability, andRBCsicklingweremonitoredover
12months of memantine administration.
2 MATERIALS AND METHODS
2.1 Patients and trial design
The pilot MemSID clinical trial (#NCT02615847 at ClinicalTrial.gov
registry) is a phase II, open-label, single-center study conducted at the
Clinic of Medical Oncology and Hematology at the Zurich University
Hospital (USZ) to evaluate the safety and tolerability of memantine
for young adult SCD patients. The protocol was approved by the local
ethics committee of Canton Zurich (KEK-ZH 2015-0297) and the reg-
ulatory authority. All participants gave signed informed consent. The
study has been conducted in accordance with local ethics committee
guidelines and theDeclaration of Helsinki. All co-authors had access to
raw data that are available on demand fromAB (annab@access.uzh.ch)
and AM (makhro@vetphys.uzh.ch).
Six adult patients presenting with symptomatic SCD were included
in the study (see Table 1 for further details). Patients P1, P2, P4, and P6
were on HU prior to the trial onset and remained on this medication
during the memantine therapy. Patients P3, and P5 were off HU treat-
ment prior and during the trial. A schematic representation of the trial
design is shown in Figure S1. Memantine dose was gradually increased
(up-dose phase) from 0 to 20mg/day over the course of 4 weeks. Max-
imal dose was maintained for 10 months (treatment phase) and then
decreased stepwise during 4 weeks from 20 to 0 mg/day (down-dose
phase).Observationswere then continuing for further 8weeks (follow-
up phase).
2.2 Clinical blood parameters
Laboratory assessments—whole blood count, red cell parameters, and
reticulocytes—were measured by an ADVIA 2100 analyzer. Plasma
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TABLE 1 Information on the patients enrolled into theMemSID trial
ID Sex Age Origin HbSS (%)
*
HbF, % (HU
dose, g/day) Trial course
P1 M 24 Angola 82.6 2.6 (1.5) Completed
P2 F 48 Kongo 81.5 14.4 (1.5) Completed
P3 M 30 Afghanistan 78.2 18 (off) Completed
P4 F 20 Ghana 84.9 8.4 (1.5) Completed
P5 F 34 Dom. Republic 75 8.8 (off) Interruption due to psychosis symptoms
P6 F 19 Angola 88 7 (1.0) Interruption due to vertigo and timing conflict
∗HbF values shown are the ones prior to the onset of memantine therapy.
lactate dehydrogenase (LDH) activity was measured using UV spec-
troscopy. Mean corpuscular hemoglobin concentration (MCHC) was
obtained based on spun hematocrit values.
2.3 Metabolic activity and K+ loss
RBCs were gently spun and washed three times with plasma-like solu-
tion supplemented with 0.1% bovine serum albumin (for details, see
Methods section in the Supporting Information). RBCs were resus-
pended in the same solution to Hb levels of 90-100 g/L, incubated in
a thermoshaker at 37◦C and under continuous shaking for 6 h. Every
hour extracellular K+ concentration was measured, and kinetics of its
accumulation plotted against time and normalized to the Hb content.
2.4 Flow cytometry for detection of CD71+ and
intracellular Ca2+
The number of RBCs positive for CD71 (reticulocytes) and intracellu-
lar free Ca2+ levels was assessed using Gallios Flow Cytometer (Bec-
tonDickensonAG, Allschwil, Switzerland) in 100 000 cells stainedwith
fluorophore-conjugated antibodies and fluo-4.
2.5 Morphology andmorphometry
Two approaches were used to evaluate RBCmorphology. Native RBCs
were imaged using bright light microscopy within 2-4 h after blood
withdrawal. Along with that RBCs were fixed with 1% glutaraldehyde
in a phosphate buffer saline solution within minutes after blood collec-
tion. Details of morphometric analysis may be found in Methods sec-
tion in the Supporting Information and in Figure S3.
2.6 RBC densitymeasured using separation on
Percoll gradients
RBCs were fractionated into low (L), medium (M), and high (H) den-
sity fractions on Percoll density gradient as described elsewhere [20].
Images of the distribution of RBCs within the gradient were taken in
front of a homogeneous light source and analyzed using ImageJ soft-
ware (see Figure S2).
2.7 Assessment of the number of NMDARs per cell
using the [3H]MK-801 binding assay
The radiolabeled NMDAR antagonist [3H]MK-801 binding assay was
used to detect the number of active receptor copies in RBCs forming
theM density fraction as described elsewhere [21].
2.8 Statistical analysis of the obtained data
All data were analyzed using the R statistical software platform [22]. A
linear mixed model using the package lme4 [23] was used to examine
the association of each clinical or laboratory variable with trial phase
(pretreatment phase, up-dose, treatment, down-dose, and follow-up).
Each patient was used as a random effect in the model implicating
repeated measure statistics. Examination of the residuals indicated
that a Gaussian model with mixed effects was a reasonable statistical
model for this analysis.
3 RESULTS
3.1 Acute effects of memantine treatment on RBCs
During the first 4 weeks of the trial, patients were administered esca-
lating doses of memantine and blood samples were taken before, 6,
and 24 h after the drug administration for patients P1-P3, P5, and
P6, whereas patient P4 was only observed weekly during the up-
dosing phase. Plasma memantine concentration was increasing with
the dose, but its pharmacokinetics varied from patient to patient
(Figure1A).During the trial, P5 exposedoneself to an involuntary over-
dose resulting in development of psychosis, which did not allow this
patient to continue the treatment. Patient P6 reported vertigo and had
difficulties to coply to the trials schedule, and dropped out shortly after
the up-dose phase. Patients 1-4 successfully completed the 12months
of memantine therapy and were observed for 2 months after the drug
administration was stopped (follow-up phase).
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F IGURE 1 Acute effects of memantine therapy. Plasmamemantine levels for SCD patients 1-6 during the up-dose phase. # stands for 1 week
after thememantine therapy was discontinued (A). Alterations in the intracellular-free Ca2+ measured as fluo-4 fluorescence intensity (B), MCHC
(C), MCV and (D) in RBCs of SCD patients 1-6 during the up-dose phase. ECell abundance in high density fraction (E). Plasma lactate
dehydrogenase (LDH) activity in patients 1-6 during the up-dose phase (F). LDH activity values showed a significant decline by the end of up-dose
period (paired t-test was applied comparing the last to the first value)
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Increment in thememantinedose triggered fluctuations in the intra-
cellular free Ca2+ measured as fluorescence intensity of Fluo-4 (Fig-
ure 1B). These changes were associated with a transient shifts in
MCHC, MCV, and abundance of dense cells (Figure 1C-E). Oscillatory
changes in LDH activity during the up-dosing phase were associated
with decrease in this hemolytic marker by the end of the first month
of memantine therapy (Figure 1F).
Treatment with memantine doses of 5-10 mg/day was associated
with a transient appearance of unusually largeRBCs in all patients (Fig-
ure 2A). This effect was transient and limited to the up-dosing phase in
all but P4 patient, for whom these large RBCs remained in the circula-
tion during the treatment phase as well (Figure 2B).
3.2 Durable effects of memantine therapy
Durable alterations in RBC properties, including RBC indices, develop-
ing over the 10months of treatment of patientswith 20mgmemantine
per day are summarized in Table 2. Some of these changes persisted
after themedicationwas stopped; some features were restored during
the down-dose and follow-up phases.
3.2.1 Reticulocyte count and changes in hemoglobin
types and levels
A sustainable decline in reticulocyte counts during the treatment
phase was observed (Figure 3A). At the same time, the proportion of
early stage reticulocytes positive for CD71 and RNA in total retic-
ulocyte population was slowly growing during the treatment phase
and was particularly high (62.9 ± 11.2%) during the follow-up phase
(Figure 3B). Memantine therapy also caused a decrease in reticulo-
cyte hemoglobinization that persisted in a follow-up phase (Figure 3C).
Decrease in reticulocyte hemoglobin content was associated with
reduction in density of mature RBCs (M fraction within Percoll gradi-
ent, Figure S2) of patients (Figure 3D).
Patient P1 was chronically receiving HU but was unable to increase
fetal hemoglobin (HbF) levels above 2% prior to the trial (Table 1),
whereas for the other patients this value ranged between 9% and 18%.
For P1, memantine therapy resulted in an increase in HbF to 8% (Fig-
ure 4). This patient benefited so much from the new treatment; he was
restored onmemantine therapy after theMemSID trial was over.
3.2.2 Changes in RBC hydration and density
Several parameters revealed alterations in RBC hydration state in the
course of durable memantine administration. Reduction in cells form-
ing heavy fraction on Percoll density gradient along with the number
of hyperchrome cells was preserved during treatment, down-dose, and
follow-up phases (Figures 5A and 5B). These changes were in line with
the decrease in MCHC levels (Figure 5C). Along with persisting reduc-
tion in passive K+ leak from the cells (Figure 5D), reduction in number
ofNMDARsper cellwasobserved in response tomemantine treatment
(Figure 6).
3.2.3 Changes in RBCmorphology
Effects ofmemantine treatment onRBCsmorphology and intracellular
Ca2+ distribution were monitored microscopically. Abundance of ter-
minally sickled cells was assessed for both glutaraldehyde-fixed RBCs
and native cells of SCD patients. Subsequently, the outcome of detec-
tion of terminally sickled cells for these two types of samples was com-
pared to avoid the artefacts of fixation (which was done immediately
after blood withdrawal) and the possible reversal from sickle to nor-
malmorphology that could occurwith timebefore the native cellswere
imaged. Eccentricity and soliditywereusedas aquantitativemarker for
detection of sickling (Figures S3B and S3C).
The number of cells with sicklemorphology declined for both native
(Figure7A) and fixed (Figure7B)RBC indicating that the observed sick-
ling was indeed irreversible. At the same time, the abundance of cells
with “normal” morphology increased for all patients by the end of the
treatment period (Figures 7C and S3).
Stabilizedmorphologywas preserved after cessation of thememan-
tine therapy. Representative images of RBC shapes of three healthy
human subjects and a SCD patients P1-P4 at screening (base) after
the treatment phase (end) and by the end of a follow-up (post) phase
are shown in Figure 8A. The complementary fluorescent images were
taken to evaluate intracellular Ca2+ distribution in RBCs of healthy
people and SCD patients. The cells of healthy donors contained exclu-
sively nanovesicles filled with Ca2+, whereas RBCs of patients before
the onset of treatment were filled with multiple larger Ca2+-storing
microvesicles (Figure 8A). The abundance of these compartments was
reduced by the end of treatment period.
As presence of NMDARs was shown for white blood cells (WBCs)
[24–28] and platelets [29] along with RBCs, we have assessed the pos-
sible effects of memantine on WBC and platelet counts. Data on the
lack of impact on the WBC and platelet counts are presented in the
Table S1.
4 DISCUSSION
We have observed several acute and durable effects of memantine
therapy on RBC properties of SCD patients. Some of these changes
most likely reflect responses of erythroid precursor cells in the bone
marrow to the NMDAR antagonist. The others are associated with the
action of the drug on the circulating RBCs. The observed changes are
schematically summarized in Figure 8B. First responseswere triggered
at plasma memantine concentrations within nanomolar range, much
lower than those (10-50 𝜇M) we have applied when monitoring the
NMDARactivity inRBCsuspensions [16,30]. In vivo, the first responses
were observed when plasma memantine concentrations reached on
average 22 nM (4.1 ± 0.8 ng/mL) for 5 mg/day dose, and persisted
at ∼378 nM (65.6 ± 16.2 ng/mL) for 20 mg/day dose. These findings
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F IGURE 2 Changes in RBCmorphology in response tomemantine treatment during the up-dosing phase. Comparison of RBCmorphology of
patient P1 before the onset of treatment (left panel) and at the up-dose phase (right panel) (A). Abnormally large cells are highlighted with the star.
Distribution of the projected areas of cells at the onset of the study, during the first day of treatment with 5mgmemantine and after a week of
administration of 5mgmemantine a day (B).
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TABLE 2 Changes in RBC indices and parameters associated with their turnover and volume regulation in response tomemantine therapy
P1 P2 P3 P4
Start End Start End Start End Start End
Retic. Hb 27.5 24.5** 27.9 26.2* – 25.4 31.0 28.6*
CD71+ retic. (%) 58.1 66.0 43.2 50.1 35.2 43.8 44.5 46.8
K+ leak, µmole/(gHbxh) 228.8 93.0*** 222.2 145.1*** 155.4 98.2** 251.4 192.1
MCHC (g/L) 343.0 321.7*** 329.1 318.5** 352.7 350.1 327.7 334.6
%Hyperchrome cells 6.46 3.27*** 2.28 2.27 8.4 5.8*** 2.0 2.0
% of cells in dense fraction 36.7 22.1** 19.0 15.4*** 39.1 26.6*** 13.9 11.3
MCV (fL) 88.6 91.2 94.6 92.9 88.7 86.9 102.2 98.9
MCH (g/L) 29.5 28.5* 30.4 29.9 31.0 29.5*** 33.1 31.2***
Macrocytes (%) 5.0 3.8 5.1 4.8 3.7 1.6*** 11.3 8.6
Microcytes (%) 5.6 5.3 2.3 2.9* 2.6 4.9*** 1.4 2.3***
Note. Average of the values from the start of theMemSID trial to the end of the up-dosing phase (base) are compared to the average from the last 3months of
treatments (20 mg/day) to the end of the down-dose phase (end). Stars denote significance (*P < .05; **P < .01, ***P < .001) between the “base” and the “end”
datasets for the individual patients (Student’s t-test orMann-Whitney Rank Sum test depending on the outcome of normality test).
Abbreviations: Retic. Hb, intracellular hemoglobin in reticulocytes; CD71+retic, immature reticulocytes positive for CD71; MCV, mean corpuscular volume;
MCH,mean corpuscular hemoglobin;MCHC, mean corpuscular hemoglobin concentration.
F IGURE 3 Impact of durable memantine therapy on reticulocytes in patients 1-4. Abundance of CD71+ reticulocytes (A), reticulocytes’
maturation state (CD71+/RNA+ cells; (B)) and their hemoglobinization (C) in SCD patients 1-4 during the treatment, down-dosing and follow-up
phases. D, Density of mature RBCs as a function of hemoglobin content of reticulocytes for cell of SCD patients onmemantine trial. Bars indicate
the treatment phase and the down-dose and follow-up periods. Significance of changes between the trial phases was assessed using a linear mixed
model in which phases were chosen as variables and patients used as a random effect. The P-values are shownwhen the treatment and
down-dose/follow-up phases were comparedwith the pretreatment phase
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F IGURE 4 Time-course of changes in HbF abundance for patient
P1 during the trial
suggest that NMDAR channel opening probability increased in RBCs
that were exposed to both agonists (glutamate and glycine) and shear
stress. These conditions most likely facilitated memantine interaction
with its binding sitewithin the channel pore. Earlier on shear stresswas
found to activate NMDARs in astrocytes and cardiomyocytes [31,32].
Influx of Ca2+ through the NMDAR is targeted by memantine
directly triggering multiple calcium-dependent signaling events. In
mature RBCs Gardos channel, inositol triphosphatase and protein
kinase C, NADPH oxidases, and calpain are among the downstream
targets of Ca2+ signaling [15]. Less is known about the Ca2+-driven
signaling cascades in erythroid precursor cells [33,34]. Monitoring of
acute response of free Ca2+ levels as well as Ca2+-dependent parame-
ters, such as RBC volume and density to memantine therapy, revealed
their acute transient changes (Figure1B-E). Eachof theseparameters is
known to have a feedback-controlledmechanism. Ca2+ uptake is coun-
teracted by channel deactivation and activation of Ca2+ pumps[35];
loss of K+ and water may be transient and activates regulatory volume
increase mechanisms [36]. Hence, instability may reflect the impact of
inhibition of NMDARs on Ca2+ handling and Ca2+-dependent param-
eters. LDH activity in plasma is a reliable marker of hemolysis in SCD
patients [37]. It shows consistent decline within the first month of
treatment (Figure 1F).
Treatment with memantine resulted in production of cells with
normal morphology and reduction in abundance of abnormal or
F IGURE 5 Effect of memantine treatment on RBC hydration state andmembranematuration in patients 1-4. Impact of durable memantine
therapy on the abundance of dense cells (A) and hyperchrome cells (B), MCHC (C), and passive K+ leakage fromRBCs (D). Significance of changes
between the trial phases was assessed using a linear mixedmodel in which phases were chosen as variables and patients used as a random effect.
The P-values are shownwhen the treatment and down-dose/follow-up phases were comparedwith the pretreatment phase. Color-coding for the
P1-P4 is similar to that in Fig. 3
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F IGURE 6 Changes in abundance of NMDARs inmature RBCs as a
result of memantine treatment. One-way repeatedmeasures ANOVA
on ranks with was applied to estimate the difference in receptor
abundance over the treatment phases (compared to the pretreatment
phase). Numbers above the graphs are the p values .
terminally sickle cells (Figure 7). Persistence of these changes as well
as of effective NMDAR shedding and low plasma LDH levels during
the follow-up phase (Figure 6) indicated that the cells produced during
memantine therapy were longer lived.
Causes for improved longevity included reprogramming of pre-
cursor cells in the bone marrow as well as the stabilization of the
circulating RBCs. Durable exposure to memantine decreased reticu-
locytes’ hemoglobin content (Figures 3A and 3C) and, in one case,
enriched with the circulating cells with HbF (Figure 4). Interrup-
tion of treatment triggered production of immature reticulocytes
(Figure 3B). Calcium-induced regulation of erythroid differentiation
has been reported to occur via calcineurin-sensitive and calcineurin-
independent Epo-inducible pathways [38] that involves and cAMP
responsive element binding protein and nuclear factor of activated
T cells (NFATc2) transcription factors [39,40,38]. Recently, participa-
tion of Ca2+-permeable channel PIEZO1 in regulation of globin gene
expression via NFAT-driven signaling cascade was reported in human
CD34+-precursors [41]. Possible involvement of this pathway in the
changes in hemoglobinization, HbF expression in reticulocytes, and
possible reduction in proliferative activity of erythroid precursors of
SCD patients uponmemantine treatment remains to be investigated.
Along with these changes in properties of erythroid cells, durable
reduction in irreversible sickling was observed in response to meman-
tine administration along with shedding from excessive NMDARs (Fig-
ure 6). Furthermore, treatment withmemantine caused a decline in K+
leak and dehydration (Figure 5D) of mature RBCs of SCD patients on
memantine treatment. These findings are in line with our former ex
vivo observations on the effect of NMDAR inhibition on RBC hydra-
tion [16,30]. In India, zinc sulfate or acetate was provided to SCD
patients for replenishment of depleted zinc stores [42–44]. This ther-
apeutic approach resulted in prevention of dehydration of RBCs. Zn2+
F IGURE 7 Morphological changes in RBCs uponmemantine
therapy in SCD patients 1-4. Percentage of elongated cells (shortest to
longest diameters R1/R2> 1.6) observed for native cells using
bright-field microscopy (A). Percentage of fixed RBCswith sickled
morphology (B). Abundance of fixed cells with normal morphology (C)
supplementation reduced the inflammation and resulted in decreased
numbers of sickle cells [45,44]. One of the targets of Zn2+ could be
NMDARs that are blocked by divalent cations in neurons, in cell cul-
tures [46,47] and in cardiac muscle [31]. Myocardial NMDARs resem-
ble the erythroid receptors in their subunit composition [31]. The
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F IGURE 8 Calcium sequestration and the impact of Ca2+-
targetingmemantine therapy on RBCs of SCD patients. (A) RBC
morphology and the intracellular Ca2+ distribution in RBC of healthy
donors (control1-control3) and for patients P1-P4 before the onset of
treatment (base), by the end of treatment (end) and by the end of
follow-up phase (post). Arrows highlight nanovesicles filled with Ca2+
in cells of healthy patients. (B) Summary on the effect of memantine on
RBC of SCD patients. Memantine therapy resulted in reduction in
hemoglobin content in reticulocytes and RBCs, a decrease in the
number of NMDARs per cell and improved hydration that was caused
by a decline in K+ leak. As a result, irreversible sickling was avoided,
and the longevity of RBCs improved
F IGURE 8 Continued
anti-inflammatory properties of Zn2+ may also be explained by the
samemechanism [48].
Targeting dehydration alone by blocking Gardos channel with Sen-
icapoc in SCD patients was proved to be insufficient to decrease
the incidence of pain episodes despite very promising amelioration in
hemolytic activity [14]. The reason of this paradoxical outcome is not
clear till now. It was suggested that an increase in hemoglobin and
hematocrit was associatedwith pathological upregulation of blood vis-
cosity, promotingVOCandpain. In our study,memantine treatment did
not cause an increase in number of RBCs (data not shown) and worked
to improve hydration state and RBC stability synergistically with HU
in few patients participating in MemSID trial. The currently running
MEMAGEN trial (#NCT03247218) will provide more insights into the
clinical potential of memantine as a supportive drug for patients with
symptomatic SCD. Furthermore, extensive trialswill be needed to eval-
uate the impact of memantine therapy on VOCs.
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